Effects of natalizumab treatment on Foxp3+ T regulatory cells.
PLoS ONE, 2008 BackgroundNatalizumab, a monoclonal humanized antibody targeting the alpha-4 chain of very late activation antigen 4 (VLA-4) exerts impressive therapeutic effects in patients with relapsing-remitting multiple sclerosis. Our objective was to study impacts
Max-Philipp Stenner +6 more
doaj +1 more source
Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
Arquivos de Neuro-Psiquiatria, 2015 Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We ...
Enedina Maria Lobato de Oliveira +5 more
doaj +1 more source
Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis
Journal of Central Nervous System Disease, 2023 Background Changes in brain connectivity occur in patients with multiple sclerosis (MS), even in patients under disease-modifying therapies. Using magnetic resonance imaging (MRI) to asses patients treated with disease-modifying therapies, such as ...
Diogo G. Corrêa +6 more
doaj +1 more source
Therapeutic Advances in Neurological Disorders, 2022 Background: For treatment of relapsing-remitting multiple sclerosis (RRMS), a broad range of disease-modifying therapies (DMT) is available. However, few comparative effectiveness studies between different drugs have been performed.
Katrin Pape +7 more
doaj +1 more source
Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? [PDF]
PLoS ONE, 2017 Progressive multifocal leukoencephalopathy (PML) is one of the major risks of natalizumab therapy. Despite introduction of the currently employed PML risk stratification algorithm, the incidence of natalizumab-associated PML cases is not decreasing.We ...
Julia Krämer +6 more
doaj +1 more source
Piloting home infusions of Tysabri (natalizumab): a randomised crossover trial
International Journal of Integrated Care, 2019 We developed a new model of care for home infusions of natalizumab for people with multiple sclerosis. The new model of care was then tested in a pilot study comparing home infusions of natalizumab with usual care (attendance in an ambulatory care day ...
Tim Schultz +8 more
doaj +1 more source
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. [PDF]
PLoS ONE, 2012 Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic
Thomas F Benkert +7 more
doaj +1 more source
Natalizumab para la esclerosis múltiple remitente-recurrente
Neurología, 2011 Resumen: Introducción: Natalizumab es un anticuerpo monoclonal inhibidor de la migración leucocitaria a través de la barrera hematoencefálica, autorizado para el tratamiento de la esclerosis múltiple remitente-recurrente. Objetivo: Realizar una revisión
A. Horga, M. Tintoré
doaj +1 more source
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
Therapeutic Advances in Neurological Disorders, 2023 Background: Natalizumab is a highly effective monoclonal antibody for the treatment of multiple sclerosis (MS), which can diffuse in different anatomical compartments, including cerebrospinal fluid (CSF) and milk.
Ilaria Callegari +12 more
doaj +1 more source
Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
PLoS ONE, 2012 In multiple sclerosis (MS), treatment with the monoclonal antibody natalizumab effectively reduces the formation of acute lesions in the central nervous system (CNS).
Lars Börnsen +6 more
doaj +1 more source